References
- Allen BC, Van Landingham C, Yang Y, Youk AO, Marsh GM, Esmen N, Gentry PR, Clewell HJ, III, Himmelstein MW. 2014. A constrained maximum likelihood approach to evaluate the impact of dose metric on cancer risk assessment: application to β-chloroprene. Regul Toxicol Pharmacol. 70(1):203–213.
- Andersen ME, Clewell HJ, III, Gargas ML, Smith FA, Reitz RH. 1987. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol. 87(2):185–205.
- Haley T. 1978. Chloroprene (2-chloro-1, 3-butadiene)-what is the evidence for its carcinogenicity? Clin Toxicol. 13(2):153–170.
- Himmelstein MW, Carpenter SC, Hinderliter PM. 2004. Kinetic modeling of beta-chloroprene metabolism: I. in vitro rates in liver and lung tissue fractions from mice, rats, hamsters, and humans. Toxicol Sci. 79(1):18–27.
- Himmelstein MW, Carpenter SC, Evans MV, Hinderliter PM, Kenyon EM. 2004. Kinetic modeling of beta-chloroprene metabolism: II. The application of physiologically based modeling for cancer dose response analysis. Toxicol Sci. 79(1):28–37.
- Munter T, Cottrell L, Golding BT, Watson WP. 2003. Detoxication pathways involving glutathione and epoxide hydrolase in the in vitro metabolism of chloroprene. Chem Res Toxicol. 16(10):1287–1297.
- Plugge H, Jaeger RJ. 1979. Acute inhalation toxicity of 2-chloro-1,3-butadiene (chloroprene): effects on liver and lung. Toxicol Appl Pharmacol. 50(3):565–572.
- Sax SN, Gentry PR, Van Landingham CV, Clewell HJ, Mundt KA. 2020. Extended analysis and evidence integration of chloroprene as a human carcinogen. Risk Anal. 40(2):294–318.
- USEPA. 2000. Vinyl chloride: CASRN 75-01-4. Washington (DC): United States Environmental Protection Agency.